Supernus Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Supernus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#343 of 15,742 sponsors by registered trial count).

57 total trials 6 currently recruiting 45 completed top decile by trial count

Supernus Pharmaceuticals: 57 sponsored US clinical trials, 6 recruiting.

Supernus Pharmaceuticals sponsors 57 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 45 completed. 26 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sialorrhea, with 2 trials.

Top-decile sponsor footprint

Supernus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#343 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

45 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

57 total, page 2 of 2

COMPLETED Phase 1

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

NCT01284530
COMPLETED Phase 1

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

NCT01107496
COMPLETED Phase 1

A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

NCT01114854
COMPLETED Phase 3

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
COMPLETED Phase 1

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

NCT00918047
COMPLETED Phase 3

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
COMPLETED Phase 2

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

NCT00626236
← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 18
Phase 3 20
Phase 4 6

Therapeutic Areas

Sialorrhea 2
Attention Deficit Hyperactivity Disorder (ADHD) 2
Postpartum Depression 2
Attention Deficit Hyperactivity Disorder 2
Focal Onset Seizures 2
Healthy Volunteer 2
Super-refractory Status Epilepticus 1
Impulsive Aggression Comorbid With ADHD in Children 1
Parkinson Disease 1

What is open in the Supernus Pharmaceuticals pipeline

6 recruiting of 57 indexed (11% open); 45 completed (79%).

Phase mix: 26 late (III/IV) vs 28 early (I/II) (balanced across stages).

Top condition: Sialorrhea (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Supernus Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 57 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Supernus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 102030405060 0%5%10%15%20% Total trials Recruiting share Supernus PharmaceuticalsEdwards LifesciencesSt. Luke's-Roosevelt Hospital CenterUSDA Grand Forks Human Nutrition Research CenterEast Carolina UniversityBastyr UniversityCorewell Health WestEthiconRowan University
Supernus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Supernus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 57 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Supernus Pharmaceuticals page

57 registered trials is a research-attention snapshot, not an endorsement of Supernus Pharmaceuticals or any single study.

  • 6 of Supernus Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sialorrhea is the condition Supernus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sialorrhea trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Supernus Pharmaceuticals pipeline card: 57 registered trials from official public datasets.Report a data error.